Ieq Capital LLC Purchases 51,637 Shares of Natera, Inc. (NASDAQ:NTRA)

Ieq Capital LLC lifted its position in shares of Natera, Inc. (NASDAQ:NTRA) by 551.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 61,005 shares of the medical research company’s stock after acquiring an additional 51,637 shares during the period. Ieq Capital LLC’s holdings in Natera were worth $9,657,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Blue Trust Inc. increased its position in Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares in the last quarter. Versant Capital Management Inc grew its stake in shares of Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after buying an additional 166 shares during the last quarter. Covestor Ltd increased its holdings in shares of Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after buying an additional 95 shares in the last quarter. Principal Securities Inc. increased its holdings in shares of Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after buying an additional 59 shares in the last quarter. Finally, True Wealth Design LLC bought a new position in shares of Natera in the 3rd quarter valued at $57,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Transactions at Natera

In other Natera news, insider Solomon Moshkevich sold 4,858 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $166.59, for a total transaction of $809,294.22. Following the completion of the sale, the insider now owns 114,912 shares in the company, valued at approximately $19,143,190.08. The trade was a 4.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Steven Leonard Chapman sold 78,553 shares of the business’s stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the sale, the chief executive officer now directly owns 267,629 shares of the company’s stock, valued at approximately $44,150,756.13. The trade was a 22.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 295,772 shares of company stock valued at $49,741,699 in the last 90 days. 7.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on NTRA shares. Guggenheim boosted their price objective on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. Piper Sandler boosted their price target on Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a report on Monday, November 18th. Robert W. Baird raised their price objective on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Finally, TD Cowen raised their price target on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and an average price target of $170.94.

Natera Stock Performance

NTRA stock opened at $168.19 on Friday. The firm has a market cap of $22.20 billion, a PE ratio of -95.56 and a beta of 1.66. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The stock has a 50-day moving average price of $168.06 and a 200-day moving average price of $144.78. Natera, Inc. has a 1-year low of $69.14 and a 1-year high of $183.00.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.